Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

The Phase IVa of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)

Phase 4

Conditions: Immunization of Inactivated EV71 Vaccine
Safety of Inactivated EV71 Vaccine

Interventions: Biological: inactivated EV71 vaccine (KMB-17)

First Posted Date: 2016-12-21

Last Posted Date: 2018-01-23

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 20770

Registration Number: NCT02999828

Locations: 🇨🇳
Chaoyang of Provincial Center for Diseases Control and Prevention in Beijing, Beijing, China

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Phase 2

Conditions: Small Cell Lung Cancer

Interventions: Drug: Apatinib Mesylate tablet

First Posted Date: 2016-12-16

Last Posted Date: 2017-09-07

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 25

Registration Number: NCT02995187

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Phase 2

Completed

Conditions: Rectal Neoplasms Malignant

Interventions: Radiation: Preoperative radiation
Drug: Raltitrexed
Procedure: Pelvic surgery

First Posted Date: 2016-12-14

Last Posted Date: 2021-09-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 68

Registration Number: NCT02992886

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China

Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01

Phase 2

Completed

Conditions: Radiotherapy; Complications
Esophagus Cancer
Esophagogastric Junction Cancer
Chemoradiation

Interventions: Radiation: SIB-IMRT
Drug: S-1

First Posted Date: 2016-12-02

Last Posted Date: 2020-07-21

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 350

Registration Number: NCT02979691

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Icotinib

First Posted Date: 2016-11-10

Last Posted Date: 2016-11-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT02961270

Locations: 🇨🇳
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Icotinib

First Posted Date: 2016-11-09

Last Posted Date: 2016-11-18

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 25

Registration Number: NCT02960607

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China

The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents

Phase 4

Completed

Conditions: Acute Lymphoid Leukemia

Interventions: Drug: PEG-rhG-CSF

First Posted Date: 2016-11-03

Last Posted Date: 2016-11-03

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 9

Registration Number: NCT02953730

Locations: 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer Recurrent

Interventions: Drug: S1 plus Docetaxel
Drug: Capecitabine plus Docetaxel

First Posted Date: 2016-10-27

Last Posted Date: 2016-10-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT02947061

Locations: 🇨🇳
No.17 panjiayuannanli, Chaoyang District, Beijing, Beijing, China

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Neoadjuvant Chemotherapy
Drug: postoperative chemotherapy

First Posted Date: 2016-10-17

Last Posted Date: 2016-10-18

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 230

Registration Number: NCT02934828

Locations: 🇨🇳
Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China

Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

Phase 2

Conditions: Esophageal Neoplasms

Interventions: Radiation: IMRT simultaneous integrated boost
Drug: Nimotuzumab
Drug: Paclitaxel
Procedure: Esophagectomy
Drug: Nedaplatin

First Posted Date: 2016-08-08

Last Posted Date: 2019-07-26

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 120

Registration Number: NCT02858206

Locations: 🇨🇳
Zefen Xiao, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy